Development Pipeline

EU CTA granted Q1 2025. First-in-human trial starting Q2 2025. Estimated completion EOY 2025.

Phase 1b/2a disease cohort to follow OX118 First-in-human trial.

Our next-generation portfolio is based on novel antibody fragment-derived constructs. These assets are intended to break new ground as first-in-class treatments for undisclosed indications in the autoimmune and immune-mediated disease fields.